Abilify Approved for Children With Bipolar Disorder

Aged 10 to 17

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, Feb. 29, 2008 (HealthDay News) -- The U.S. Food and Drug Administration has approved Abilify (aripiprazole) to treat manic and mixed episodes in children aged 10 to 17 with bipolar 1 disorder, makers Otsuka Pharmaceutical Co. and Bristol-Myers Squibb Inc. said Friday.

The drug has been approved for this and other uses in adults for several years.

The new approval was based on results from a four-week study involving children in this age group. The trial demonstrated the drug's effectiveness compared to a placebo, the drug companies said in a statement.

Abilify was first approved in November 2002, and nearly 15 million prescriptions had been written through December 2007, the statement said.

More information

The FDA has more about this drug.


Last Updated: